Acute Lymphoblastic Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)

The acute lymphoblastic leukemia (ALL) therapy market is entering a dynamic period of growth driven by the introduction of targeted agents and nextgeneration cell therapies. Widely used immunotherapies such as Amgen’s Blincyto and Pfizer’s Besponsa remain central to current treatment regimens. Alongside established CAR Tcell therapies, including Kymriah and Tecartus, the approval of Aucatzyl is reshaping expectations for adult patients with relapsed/refractory (R/R) Bcell disease. The 2024 FDA approval of the menin inhibitor revumenib for KMT2Arearranged R/R ALL offers a novel option. The emerging therapy pipeline continues to expand, with CAR Tcell candidates such as Cellectis’s lasmecabtagene timgedleucel targeting CD22, alongside Wugen’s soficabtagene geleucel and Imviva’s CTD-402, both directed at CD7. These developments underscore an innovationdriven market focused on precisionengineered therapies that address persistent unmet needs in ALL.

Questions answered

• What is the size of the drug-treatable ALL population, and how do the drug-treatment rates vary by geography, line of therapy, and age?
• How will the use of chemotherapy change over the forecast period, and what impact will generic entry have on the ALL market?
• What are thought leaders’ opinions of anti-CD19 CAR T-cell therapies that are approved or in Phase 2 or 3 development, such as Kymriah, Tecartus, and Breyanzi?
• What are the drivers of, and constraints on, the ALL market?
• How will the entry of new agents shape this market?

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.